Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$31.59
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | PFE Avg Daily Volume: 24,690,400
Last Update: 12/05/16 - 4:02 PM EST
Volume: 0
YTD Performance: -2.14%
Open: $0.00
Previous Close: $31.59
52 Week Range: $28.25 - $37.39
Oustanding Shares: 6,068,355,132
Market Cap: 191,942,072,825
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 7
Moderate Buy 0 0 0 0
Hold 8 9 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.13 1.92 1.92
Latest Dividend: 0.30
Latest Dividend Yield: 3.79%
Dividend Ex-Date: 11/08/16
Price Earnings Ratio: 15.13
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
15.13 31.30 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.15% -3.69% 1.09%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.50 $0.62 $2.41 $2.60
Number of Analysts 8 2 8 11
High Estimate $0.54 $0.64 $2.43 $2.67
Low Estimate $0.47 $0.60 $2.38 $2.45
Prior Year $0.53 $0.67 $2.20 $2.41
Growth Rate (Year over Year) -5.42% -7.46% 9.55% 7.70%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | Nov 29, 2016 | 2:24 PM EST
Market should still be able to breathe once central-bank prop is removed.
By

Bruce Kamich

 | Nov 29, 2016 | 9:52 AM EST
A new period of accumulation and sideways price action is likely needed before any upside movess.

bullishPfizer upgraded at Barclays

Nov 29, 2016 | 7:47 AM EST
PFE was upgraded from Equal-weight to Overweight, Barclays said. $38 price target. Company should be able to use foreign cash to boost returns and the oncology business will drive growth.
RMPIA
By

Bret Jensen

 | Nov 28, 2016 | 11:00 AM EST
Small-caps could also benefit from abating tax-loss selling.
By

Tim Melvin

 | Nov 10, 2016 | 12:00 PM EST
Firms' 13F filings show how they've followed in the footsteps of the father of value investing.
By

Christopher Versace

 | Nov 9, 2016 | 12:00 PM EST
As we all know, the stock market and the economy abhor uncertainty.
By

Jim Cramer

 | Nov 9, 2016 | 5:58 AM EST
But don't buy blindly. There are too many companies that can be retaliated against.
RMPIA
By

Jim Cramer

 | Nov 4, 2016 | 7:13 AM EDT
Stocks in the health care sector seem to have no underpinnings whatsoever.
RMPIA
By

Jim Cramer

 | Nov 3, 2016 | 1:58 PM EDT
And if it's lost, good luck getting it back.
By

Jim Cramer

 | Nov 2, 2016 | 1:09 PM EDT
Jim Cramer says Zoetis, an animal health company, is well run.
BC is moving well today.  Shares are up over 3.5% on fairly heavy trade and are tradi...
Markets taking the latest rejection of the status quo in Italy in stride as the reforms we...
Merck continues to retreat from November's failed breakout.  Back on 9th and 10th of ...
Trifecta Stocks name Disney is bumping up to the 100 area hereon some good turnover and bu...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.